To the Editor: Khatri’s and Stuckey’s 1 article, Vertebral fractures after denosumab discontinuation for dental procedures: a consequence of distorted perceptions of risk , sums up the authors’ knowledge and experience of medication‐related osteonecrosis of the jaws (MRONJ) in the latter part of the title. They quote the risk of MRONJ as being very low and equal for denosumab and oral bisphosphonates. This is incorrect. The risk of MRONJ is 0.3%. 2 In our study we found the risk following extractions at 1.8%. 3 The recent 2022 update of the position paper on MRONJ 4 found that the risk with denosumab is an order of magnitude higher than for bisphosphonates.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the 炉石传说电竞之星 is now provided through Wiley Online Library.
Publication of your online response is subject to the Medical Journal of Australia 's editorial discretion. You will be notified by email within five working days should your response be accepted.
No relevant disclosures.